tocilizumab - for COVID-19   method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 1.07 [0.70, 1.63]< 10%4 studies (4/-)37.8 %some concernnot evaluable moderatecrucial-
clinical improvement 1.12 [0.95, 1.33]> 10%3 studies (3/-)91.6 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.19 [0.81, 1.75]> 10%1 study (1/-)81.0 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.15 [0.90, 1.47]> 10%1 study (1/-)86.8 %some concernnot evaluable moderateimportant-
clinical worsening 0.78 [0.53, 1.14]< 136%4 studies (4/-)90.2 %some concernnot evaluable moderateimportant-
death or ventilation 0.62 [0.42, 0.93]< 10%3 studies (3/-)99.0 %some concernnot evaluable moderateimportant-
hospital discharge 1.16 [0.90, 1.49]> 10%1 study (1/-)87.9 %some concernnot evaluable moderateimportant-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 2 pathologies: 87,95,94,90,91,97 91, 90